Guidance on the use of factor V leiden and prothrombin mutation testing in patients with a first unprovoked thromboembolic episode
To assist decision-makers considering implementation or reassessment of factor V Leiden (FVL) and prothrombin gene (PG) mutation testing practices, CADTH's Health Technology Expert Review Panel (HTERP) developed evidence-informed guidance on the optimal use of these tests for patients with unpr...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
March 2015, 2015
|
| Series: | CADTH optimal use report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | To assist decision-makers considering implementation or reassessment of factor V Leiden (FVL) and prothrombin gene (PG) mutation testing practices, CADTH's Health Technology Expert Review Panel (HTERP) developed evidence-informed guidance on the optimal use of these tests for patients with unprovoked venous thromboembolism (VTE). The clinical and economic evidence used for developing guidance was derived from the following CADTH report: 1. The CADTH Optimal Use report: Effectiveness of Factor V Leiden and Prothrombin Mutation Testing in Patients Presenting with Unprovoked First Thromboembolic Episode, consisting of a systematic review of the clinical evidence and an economic analysis. HTERP considered the evidence and its limitations from a population-based perspective |
|---|---|
| Item Description: | "This report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH)"--T.p. verso |
| Physical Description: | 1 PDF file (i, 10 pages) |